[Form 4] iTeos Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Rhoads Ann D, a director of iTeos Therapeutics, reported on 08/29/2025 the cancellation and cash-out of her outstanding in-the-money stock options in connection with the companys merger with Concentra Biosciences LLC. The Form 4 shows 27,178 stock options with an exercise price of $6.16 were disposed of and the reporting person holds 0 options following the transaction. Under the Merger Agreement, in-the-money options (exercise price below $10.047 cash per share) were cancelled and optionholders received a cash payment equal to (Cash Amount minus exercise price) times underlying shares, plus one non-transferable contingent value right (CVR) per underlying share.

Positive

• Merger closed consideration provided immediate cash value to optionholders based on a $10.047 per-share cash amount
• Outstanding in-the-money options removed, which reduces potential future dilution from those options

Negative

• Reporting person no longer holds the 27,178 options after cancellation (reported beneficial ownership = 0)
• Future upside replaced by non-transferable CVRs, which may limit liquidity and transferability compared with common stock

Insights

Financial Analyst

TL;DR: Directors in-the-money options were cashed out as part of a merger, converting equity-linked compensation into cash plus CVRs.

The Form 4 documents a routine but material corporate action where 27,178 options at $6.16 were settled for cash due to a merger with Concentra Biosciences LLC. The cash settlement used a per-share "Cash Amount" of $10.047, with optionholders receiving the spread times shares plus one CVR per share. For analysts, this removes potential future dilution from these options and transfers future upside (if any) to the CVR structure rather than exercisable equity. The immediate effect is a reduction in reported insider derivative holdings to zero.

Corporate Governance Expert

TL;DR: Cancellation and cash settlement of in-the-money options is a common merger treatment; it closes outstanding option positions for insiders.

From a governance perspective, the Form 4 shows the company implemented merger consideration consistent with the Merger Agreement: in-the-money options were cancelled in exchange for cash and contractual CVRs. The filing was executed by an attorney-in-fact and properly discloses the nature of the consideration. This action changes insider holdings and replaces vested option upside with a contractual right (CVR), which may carry different governance and transferability features.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RHOADS ANN D

(Last) (First) (Middle)

C/O ITEOS THERAPEUTICS, INC.

321 ARSENAL STREET

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
iTeos Therapeutics, Inc. [ ITOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.16	08/29/2025		D(1)(2)			27,178	(1)(2)	(1)(2)	Common Stock	27,178	(1)(2)	0	D

Explanation of Responses:

1. This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company ("Company Stock Options," and each such option, a "Company Stock Option") that had an exercise price per share that is less than $10.047 in cash per share (the "Cash Amount") (each, an "In-the-Money Option")

2. (Continued from footnote 1) that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option.

	/s/ Adi Osovsky, as Attorney-in-Fact	08/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 filed for ITOS report?

The Form 4 reports the cancellation and cash settlement of 27,178 stock options held by director Rhoads Ann D on 08/29/2025, leaving 0 options owned following the transaction.

Why were the options cancelled for cash in the ITOS merger?

Under the Merger Agreement, each in-the-money option (exercise price below $10.047) was cancelled and optionholders received cash equal to (Cash Amount minus exercise price) times underlying shares, plus one CVR per share.

What was the exercise price of the options disposed of by the reporting person?

The reported exercise price for the disposed stock options was $6.16.

What is a CVR mentioned in the Form 4?

The Form 4 states optionholders received one non-transferable contractual contingent value right (CVR) per underlying share as part of the merger consideration.

Who signed the Form 4 filing for the reporting person?

The Form 4 was signed by Adi Osovsky as attorney-in-fact on behalf of the reporting person on 08/29/2025.